New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
ROTH Healthcare Corporate Access Day to be held in London, England on June 23-24.
Check below for free stories on ACRX;BLRX;CRIS;NEO;PRTA;PTCT;LGND;GALE;IPCI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 21, 2014
07:03 EDTBLRXBioLineRx receives Notice of Allowance for BL-7010 U.S. patent
Subscribe for More Information
05:32 EDTGALEGalena fired CEO over stock promotion scandal, Feuerstein says
Galena fired its CEO Mark Ahn following a stock promotion scandal, The Street's Adam Feuerstein reported last night, citing a source close to the company. A public announcement is coming today, Feuerstein added.
August 19, 2014
07:06 EDTACRXGuggenheim to hold a conference
Subscribe for More Information
August 18, 2014
10:57 EDTACRXOptions with decreasing implied volatility
Subscribe for More Information
08:52 EDTPTCTPTC Therapeutics price target raised to $43 from $34 at Roth Capital
Subscribe for More Information
August 15, 2014
09:31 EDTLGNDLigand, Avion Pharmaceuticals sign Captisol license agreement
Subscribe for More Information
08:41 EDTNEONeoGenomics 7M share Spot Secondary priced at $4.60
The deal size was increased to 7M shares from 5M shares and was priced at $4.60. William Blair acted as lead book running manager for the offering.
August 14, 2014
16:02 EDTNEONeoGenomics files to sell common stock, no amount given
NeoGenomics anticipates using the net proceeds from the offering for working capital, capital expenditures and other corporate purposes, including potential acquisitions and the repayment of debt. William Blair & Company, L.L.C. is the sole book-running manager and Craig-Hallum Capital Group LLC is co-lead manager for the offering. Stephens Inc., Roth Capital Partners, LLC, Sidoti & Company, LLC and Dawson James Securities, Inc. are serving as co-managers for the offering.
08:12 EDTLGNDLigand signs multi-program Captisol license agreement with Avion Pharmaceuticals
Subscribe for More Information
August 12, 2014
09:57 EDTPTCTPTC Therapeutics management to meet with Oppenheimer
Meeting to be held in Toronto on August 18 hosted by Oppenheimer.
07:44 EDTLGNDMarinus Pharmaceuticals enters into agreement with CyDex Pharmaceuticals
Marinus Pharmaceuticals (MRNS) announced that it has entered into an agreement with CyDex Pharmaceuticals, a wholly owned subsidiary of Ligand Pharmaceutical (LGND), for the clinical use of Captisol, a patent protected, uniquely modified cyclodextrin, whose chemical structure was designed to improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients. Marinus intends to evaluate optimizing its intravenous dose form of ganaxolone with Captisol.
August 11, 2014
18:29 EDTGALEOn The Fly: After Hours Movers
UP AFTER EARNINGS: DealerTrack (TRAK), up 11.3%... DTS Inc. (DSTI), up 12.8%... Globalstar (GSAT), up 1.6%... Halozyme Therapeutics (HALO), up 2.4%. ALSO HIGHER: Intercept Pharmaceuticals (ICPT), up 57.7% after announcing that 46% of OCA group met FLINT endpoint as well as reporting second quarter results... Cempra (CEMP), up 5.8% following Intercept Pharmaceuticals' FLINT announcement... Scotts Miracle-Gro (SMG), up 3.6% after board approves a $500M share repurchase authorization and announces a $2.00 per share special dividend. DOWN AFTER EARNINGS: Galena Biopharma (GALE), down 13.4%... Nuance Communications (NUAN), down 9.7%... Millennial Media (MM), down 7.1%... MasTec (MTZ), down 3.6%... Turtle Beach (HEAR), down 3.5%... magicJack (CALL), down 5.8%... Geron (GERN), down 2.4%. ALSO LOWER: Sprouts Farmers Market (SFM), down 3.7% after filing to sell 15M shares of common stock for holders.
16:38 EDTGALEGalena reports Q2 EPS (17c), consensus (9c)
Subscribe for More Information
16:11 EDTLGNDLigand announces $200M share repurchase plan
Subscribe for More Information
16:11 EDTLGNDLigand files to sell $225M of convertible senior notes due 2019
Subscribe for More Information
16:05 EDTACRXAcelRx says disappointed on Zalviso CRL, to meet with FDA in September
"We were disappointed with the receipt of a Complete Response Letter for Zalviso and we look forward to meeting with the FDA to clarify the items included in the CRL and to discuss our planned response," stated Richard King, president and CEO of AcelRx. "We have spoken to the FDA and plan to meet with them by the end of September 2014. We anticipate we can refile the Zalviso NDA before the end of 2014, pending the outcome of the meeting with the FDA. We remain confident in the Zalviso development program and will work closely with the FDA to address the Agency's concerns as outlined in the CRL to ensure that healthcare professionals and patient communities will have access to Zalviso." The company reiterates and issues financial guidance for the year for total operating expenses to be in the range of $48M-$52M. Estimates cash, cash equivalents and investment balances at December 31 of at least $65M.
16:03 EDTACRXAcelRx reports Q2 EPS (30c), consensus (26c)
Subscribe for More Information
15:27 EDTPTCTWedbush to hold a conference
Life Sciences Management Conference to be held in New York on August 12-13.
05:53 EDTCRISCuris shares look attractive, says Piper Jaffray
Subscribe for More Information
August 8, 2014
08:59 EDTCRISCuris weakness creates buying opportunity, says Oppenheimer
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use